Sun Pharma Advanced Research Company Limited
NSE: SPARC BSE: SPARC
NSE
152.84
2.91 (1.94%)
Prev Close
149.93
Open Price
151
Volume
505,473
Today Low / High
150.65 / 153.22
52 WK Low / High
109.3 / 315.95
Range
145 - 160
BSE
152.80
2.75 (1.83%)
Prev Close
150.05
Open Price
150.05
Volume
42,955
Today Low / High
150.05 / 153.1
52 WK Low / High
109.2 / 317
Range
145 - 160
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 152.84 (target range: 145 - 160), reflecting a change of 2.91 (1.94091%). On the BSE, it is listed at 152.8 (target range: 145 - 160), showing a change of 2.75 (1.83272%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
151.00
1.22%
17 Apr
150.36
-0.29%
16 Apr
149.65
0.47%
15 Apr
146.90
0.74%
11 Apr
148.00
-1.70%
09 Apr
142.00
1.15%
08 Apr
146.86
-2.57%
07 Apr
131.13
8.73%
04 Apr
150.00
-2.97%
03 Apr
147.19
1.91%
02 Apr
147.45
-1.25%
01 Apr
146.40
-0.08%
28 Mar
151.50
-2.37%
27 Mar
147.33
2.31%
26 Mar
153.00
-3.46%
25 Mar
156.50
-1.71%
24 Mar
146.80
6.29%
Sun Pharma Advanced Research Company Limited Graph
Sun Pharma Advanced Research Company Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sun Pharma Advanced Research Company Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 152.84, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 152.80 | 154.33 | 138.90 - 169.76 |
| 155.86 | 124.68 - 187.03 | ||
| 157.38 | 110.17 - 204.60 | ||
| Bearish Scenario | 152.80 | 151.27 | 136.14 - 166.40 |
| 149.74 | 119.80 - 179.69 | ||
| 148.22 | 103.75 - 192.68 |
Overview of Sun Pharma Advanced Research Company Limited
ISIN
INE232I01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,198,461
Market Cap
49,599,942,480
Last Dividend
0
Official Website
IPO Date
2003-01-14
DCF Diff
240.17
DCF
-88
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 75.55 Cr | 199.37 Cr | -123.82 Cr | -1.6391 | 479.34 Cr | 154.48 Cr | -411.50 Cr | -387.21 Cr | -11.93 | -373.15 Cr | -5.1256 |
| 2023-03-31 | 230.78 Cr | 171.58 Cr | 59.20 Cr | 0.2565 | 452.84 Cr | 131.95 Cr | -214.95 Cr | -222.58 Cr | -7.82 | -203.18 Cr | -0.9645 |
| 2022-03-31 | 137.25 Cr | 126.70 Cr | 10.55 Cr | 0.0769 | 324.00 Cr | 69.52 Cr | -196.91 Cr | -203.40 Cr | -7.73 | -179.90 Cr | -1.4819 |
| 2021-03-31 | 252.96 Cr | 206.40 Cr | 46.56 Cr | 0.1840 | 387.93 Cr | 51.93 Cr | -145.90 Cr | -151.14 Cr | -5.77 | -129.57 Cr | -0.5975 |
| 2020-03-31 | 76.81 Cr | 193.22 Cr | -116.41 Cr | -1.5155 | 386.83 Cr | 43.92 Cr | -314.95 Cr | -312.40 Cr | -11.92 | -300.25 Cr | -4.0670 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 5.33 Cr | 515.04 Cr | 389.29 Cr | 125.7554 Cr | 61.15 Cr | 55.82 Cr | 0.00 Cr | 108.62 Cr | 16.68 Cr | 103.49 Cr | 0.00 Cr | 265.0578 Cr |
| 2023-03-31 | 0.58 Cr | 830.12 Cr | 317.35 Cr | 512.7700 Cr | 15.67 Cr | 15.09 Cr | -4.17 Cr | 107.28 Cr | 18.22 Cr | 117.65 Cr | -228.64 Cr | 178.9400 Cr |
| 2022-03-31 | 1.22 Cr | 280.08 Cr | 248.86 Cr | 31.2257 Cr | 79.21 Cr | 77.99 Cr | 0.00 Cr | 95.12 Cr | 16.71 Cr | 66.85 Cr | 8.67 Cr | 171.4289 Cr |
| 2021-03-31 | 9.30 Cr | 229.69 Cr | 397.94 Cr | -168.2516 Cr | 236.38 Cr | 227.08 Cr | 3.32 Cr | 95.11 Cr | 9.80 Cr | 39.24 Cr | 0.40 Cr | 233.3517 Cr |
| 2020-03-31 | 0.35 Cr | 272.56 Cr | 291.20 Cr | -18.6383 Cr | 68.34 Cr | 67.99 Cr | -16.82 Cr | 106.56 Cr | 8.20 Cr | 39.24 Cr | 0.00 Cr | 235.3554 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | -429.1883 Cr | 391.5271 Cr | 42.4051 Cr | -455.6962 Cr | 4.7459 Cr | 5.3295 Cr | -26.5079 Cr | -387.2139 Cr | 46.9490 Cr | 0.0000 Cr | 0.0000 Cr |
| 2023-03-31 | -69.1200 Cr | -548.2800 Cr | 616.7600 Cr | -84.5100 Cr | -0.6400 Cr | 0.5800 Cr | -15.3900 Cr | -222.5800 Cr | -74.9490 Cr | 0.0000 Cr | 0.0019 Cr |
| 2022-03-31 | -208.2325 Cr | -29.1670 Cr | 229.3209 Cr | -240.9104 Cr | -8.0803 Cr | 1.2242 Cr | -32.6779 Cr | -203.3954 Cr | -155.5452 Cr | 0.0000 Cr | 0.0000 Cr |
| 2021-03-31 | -151.8956 Cr | 1.5618 Cr | 159.2843 Cr | -157.8907 Cr | 8.9522 Cr | 9.3045 Cr | -5.9951 Cr | -151.1388 Cr | 169.4405 Cr | 0.0000 Cr | 0.0000 Cr |
| 2020-03-31 | -210.8054 Cr | 155.3463 Cr | 55.4618 Cr | -264.8481 Cr | 0.0027 Cr | 0.3523 Cr | -54.0427 Cr | -312.4034 Cr | 57.4253 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 14.91 Cr | 30.36 Cr | -15.45 Cr | -1.0362 | -76.83 Cr | -79.51 Cr | -2.45 | -73.50 Cr | -5.3327 |
| 2024-09-30 | 12.86 Cr | 49.95 Cr | -37.09 Cr | -2.8841 | -106.07 Cr | -107.33 Cr | -3.31 | -102.87 Cr | -8.3460 |
| 2024-06-30 | 16.81 Cr | 61.93 Cr | -45.12 Cr | -2.6841 | -96.50 Cr | -95.90 Cr | -2.96 | -91.80 Cr | -5.7049 |
| 2024-03-31 | 16.56 Cr | 60.56 Cr | -44.00 Cr | -2.6570 | -108.90 Cr | -105.79 Cr | -3.26 | -101.43 Cr | -6.3883 |
| 2023-12-31 | 13.86 Cr | 32.74 Cr | -18.88 Cr | -1.3622 | -99.39 Cr | -99.65 Cr | -3.07 | -96.23 Cr | -7.1898 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 5.67 Cr | 0.40 Cr | 6.07 Cr | 13.61 Cr | 0.00 Cr | 90.55 Cr | 104.65 Cr | 320.81 Cr | 398.19 Cr |
| 2024-06-30 | -157.13 Cr | 314.26 Cr | 157.13 Cr | 0.00 Cr | 0.00 Cr | 157.13 Cr | 0.00 Cr | 0.00 Cr | -125.76 Cr |
| 2024-03-31 | 155.33 Cr | 1.80 Cr | 157.13 Cr | 58.55 Cr | 1.48 Cr | 269.38 Cr | 108.61 Cr | 515.04 Cr | 389.29 Cr |
| 2023-12-31 | -366.10 Cr | 732.20 Cr | 366.10 Cr | 0.00 Cr | 0.00 Cr | 366.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1.31 Cr | 377.21 Cr | 378.52 Cr | 31.70 Cr | 0.00 Cr | 442.57 Cr | 108.55 Cr | 667.41 Cr | 335.73 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | -95.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -105.79 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -99.65 Cr | 6.32 Cr | 0.00 Cr | 0.00 Cr | 6.32 Cr | 221.00 Cr | 214.68 Cr | 0.00 Cr | 6.32 Cr |
| 2023-09-30 | -86.42 Cr | 6.36 Cr | 0.00 Cr | 0.00 Cr | 6.36 Cr | 214.68 Cr | 208.32 Cr | 0.00 Cr | 6.36 Cr |
| 2023-06-30 | -95.35 Cr | 6.20 Cr | 0.00 Cr | 0.00 Cr | 6.20 Cr | 6.79 Cr | 0.59 Cr | 0.00 Cr | 6.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2012-08-23 | August 23, 12 | 127:125 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Chief Innovation Officer
Dr. Nitin K. Damle Ph.D.
Gender: Not Specified
Year Born:
Head Clinical Development
Mr. Siu-Long Yao
Gender: male
Year Born:
Senior General Manager of Business Development, Corporate Communication & Investor Relations
Mr. Jaydeep Issrani
Gender: male
Year Born:
Head of Preclinical Development
Dr. Vikram K. Ramanathan
Gender: Not Specified
Year Born:
Chief Operating Officer
Dr. Nitin Dharmadhikari
Gender: Not Specified
Year Born: 1962
Company Secretary & Compliance Officer
Ms. Kajal K. Damania
Gender: female
Year Born:
Head of Drug Delivery Systems
Dr. Yashoraj Zala
Gender: Not Specified
Year Born:
Chief Human Resource Officer
Ms. Shanta Gupta
Gender: female
Year Born:
Chief Financial Officer
Mr. Anup Rathi
Gender: male
Year Born:
Chief Executive Officer
Mr. Anilkumar Raghavan
Gender: male
Year Born: 1968
FAQs about Sun Pharma Advanced Research Company Limited
Who is the CEO of the company?
The CEO is Mr. Anilkumar Raghavan.
What is the current market price of the stock?
The current price is ₹152.84.
What is the 52-week price range?
The range is ₹109.3-315.95.
What is the market capitalization of the company?
The market capitalization is ₹4,959.99 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -12.77.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Sun Pharma Advanced Research Company Limited (ISIN: INE232I01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,959.99 crores and an average daily volume of 2,198,461 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.